Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection

Next Previous
Trial Profile

A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Clostridium difficile infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PUNCHCD3
  • Sponsors Rebiotix

    • Most Recent Events

    • 23 Oct 2023 Ad hoc analysis results presented in a Ferring Pharmaceuticals media release.
    • 23 Oct 2023 According to a Ferring Pharmaceuticals media release, the poster of ad hoc analysis were presented at the American College of Gastroenterology's (ACG) 2023 Annual Scientific Meeting.
    • 11 Oct 2023 According to a Ferring Pharmaceuticals media release, company announced four poster presentations at Infectious Disease Week (IDWeek) 2023 for REBYOTA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top